Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

计划入组 8 人 · 首次发布于 2021 年 11 月 30 日

Left Main Intervention in Myocardial Infarction and Acute Coronary Syndromes

计划入组 500 人 · 首次发布于 2023 年 1 月 27 日

LGG/BB12-pastille Study

计划入组 60 人 · 首次发布于 2012 年 4 月 13 日

LGN-20

UGN-201 + UGN-301

SGN-BB228

Ligand Pharmaceuticals

United States

Lin BioScience, Inc.

China

LGM Pharmaceuticals, Inc.

United States

Ultrasound-Activated Nanoparticles Enable Precise Drug Delivery to Deep Brain Regions in Primates

Ligand Pharmaceuticals Leads $75M Royalty Financing for D-Fi Gene Therapy in Rare Skin Disease Trial

Ligand Pharmaceuticals Director Sells 2,501 Shares in Pre-Planned Option Exercise — What the Royalty-Driven Biotech Model Means for Investors